Press Release

View printer-friendly version << Back

vTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity

PDF Version

HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected for oral and poster presentations on its diabetes product candidates, TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity. The symposia will take place from April 17 – 20, 2016 in La Jolla, CA.

TTP273

Oral Presentation Details:

  • Presentation Title: Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting
  • Session Date: Wednesday, April 20, 2016
  • Session Time: 8:30 a.m. - 11:30 a.m. PDT

Poster Details:

  • Poster Title: Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting
  • Poster Number: 1025
  • Poster Session: 1
  • Session Date: Monday, April 18, 2016
  • Session Time: 11:45 a.m. - 10:00 p.m. PDT

TTP399

Poster Details:

  • Poster Title: The Importance of Tissue Selectivity and Preservation of the Physiological Regulation when Targeting Key Metabolic Regulators as Glucokinase
  • Poster Number: 2040
  • Poster Session: 2
  • Session Date: Tuesday, April 19, 2016
  • Session Time: 11:30 a.m. - 10:00 p.m. PDT

A copy of the posters will be made available in the News & Events section of the Company’s website following the presentations.

About Type 2 Diabetes

Type 2 diabetes is the body’s inability to properly use insulin to control sugar in the bloodstream. It is the most common type of diabetes (representing 90 to 95% of diabetes patients), imposing a growing burden on healthcare systems globally. The goal of maintaining A1c levels below 7.0% is elusive for patients with this life-long disease. In addition to unregulated glucose, diabetics commonly have a variety of co-morbidities, including heart disease, stroke, high blood pressure, blindness, kidney disease, amputations, dental disease, and central and peripheral nervous system impairment.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Source: vTv Therapeutics Inc.

Investors
The Trout Group
Adam Krop, 646-378-2963
akrop@troutgroup.com
or
Media
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com